Bladder cancer

#Bladder cancer #Covid-19 #Drug discovery #Heart disease #Lung disease #Oncology

This week in Drug Discovery (22-26 June) 

News round-up for 22–26 June by Bruno Quinney, Content Team at DDW.  This week, the Summer issue of DDW is now available to read. Elsewhere, researchers have uncovered clues explaining risks of heart disease, lung disease, Covid-19 and cancer.    The top stories: … Read More

#News

Bladder cancer
#Bladder cancer #Oncology #University of Edinburgh #Xiamen University

Algae microbots increase drug penetration 10x in bladder cancer

Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs into tumours, researchers say.   Tracked using real-time imaging, the miniature robots help drugs penetrate deep into tumour tissue while limiting damage to healthy cells.   In lab tests with… Read More

#Cancer Research #Editor's Choice #News

Bladder
#AstraZeneca #Bladder cancer #European Commission #Monoclonal antibodies #Oncology

EU-approved bladder cancer therapy reduces death risk by 25%

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment.  According to the decision, this treatment should be followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery… Read More

#Cancer Research #News #Regulatory

Bladder cancer
#AstraZeneca #Bladder cancer #FDA #Monoclonal antibodies #Oncology

Imfinzi approval a ‘breakthrough’ for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).  It is approved in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder). … Read More

#News #Regulatory

Prostate cancer cells
#Bladder cancer #Immunotherapy #Oncology #Prostate cancer #UCLA

Immunotherapy with chemotherapy effective for rare cancers

New research has found that combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate. A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with… Read More

#Cancer Research #Editor's Choice #News

Bladder
#Bladder cancer #Johnson & Johnson #MHRA #Oncology #Phase III trial

MHRA approves erdafitinib for some urothelial carcinomas

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Balversa (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC). Specifically, the indication covers patients harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, who have previously received… Read More

#News #Regulatory

Bladder cancer
#Bladder cancer #Drug repurposing #Mouse models #Oncology #Preclinical investigations

Diabetes and cancer drug combo shrinks bladder tumours by 91%

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) in New York has identified a promising drug combination for the treatment of muscle-invasive bladder cancer. Rosiglitazone plus trametinib worked synergistically to not only induce tumour cell death, but also shift… Read More

#Cancer Research #Editor's Choice #News

Bladder
#Bladder cancer #CHMP #Genetics / genomics #Janssen #Oncology

CHMP okays first therapy targeting FGFR3 alterations in bladder cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Janssen-Cilag’s Balversa (erdafitinib). It is recommended as a monotherapy to treat adult patients with unresectable or metastatic urothelial carcinoma, harbouring susceptible FGFR3 genetic alterations who have previously received at… Read More

#News #Regulatory

Bladder
#Astellas Pharma #Bladder cancer #Japan #Oncology #Regulatory #Urothelial carcinoma

Japanese regulator reviews first-line bladder cancer combination

Astellas has submitted a supplemental new drug application (sNDA) in Japan for Padcev (enfortumab vedotin (genetical recombination)) with Keytruda (pembrolizumab (genetical recombination)) for the first-line treatment of advanced bladder cancer. If approved, it would be the first combination in Japan to offer an alternative to chemotherapy, the current standard of… Read More

#News #Regulatory

#Antibody drug conjugate (ADC) #Bladder cancer #Breast cancer #Depression #Menopause #Oncology #Psychedelics #Women's health

New DDW Highlights podcast for 27 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  There have been some ground-breaking advances in women’s health this week, with new treatments… Read More

#News

#Antibody drug conjugate (ADC) #Bladder cancer #Breast cancer #Depression #Menopause #Oncology #Psychedelics #Women's health

This week in drug discovery (18-22 December) 

News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. In… Read More

#News

Bladder cancer
#Antibody drug conjugate (ADC) #Astellas Pharma #Bladder cancer #FDA #Oncology #Pfizer #Phase III trial

Bladder cancer therapy reduces risk of death by 50%

The US Food and Drug Administration (FDA) has approved antibody-drug conjugate (ADC) enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer (la/mUC). The approval is based on clinical data which found that Padcev plus pembrolizumab nearly doubled median overall survival compared to… Read More

#Editor's Choice #News #Regulatory

Bladder cancer
#Bladder cancer #EMA #Janssen #Marketing approval authorisation #Regulatory #Urothelial carcinoma

Janssen submits EMA filing for bladder cancer treatment 

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3)… Read More

#Cancer Research #News